SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia

Completed · Phase 1/Phase 2

Conditions studied: Anal Cancer

In brief

Phase I/II trial to study the effectiveness of SGN-00101 in preventing anal cancer in HIV-positive patients who have high-grade anal neoplasia. Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. SGN-00101 may be effective in preventing anal cancer.

Key facts

Study ID

NCT00052897

Run by

National Cancer Institute (NCI)

People needed

18

Starts

2002-12-01

Last updated by the study team

2013-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• UCSF Comprehensive Cancer Center — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.